Madrigal Pharmaceuticals event puts genetics in focus Madrigal Pharmaceuticals (MDGL) drew fresh attention after publishing a ...
Madrigal Pharmaceuticals recently reported in the Journal of Hepatology that a pre-specified secondary analysis of the Phase ...
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants ...
For Madrigal Pharmaceuticals (MDGL-0.06%) stock to take off, three things need to happen: Sales of Rezdiffra need to keep growing; the drug needs to expand to patients with cirrhosis caused by ...
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
Older GLP-1s are also set to muscle in on this latent MASH market. (eranicle/iStock/Getty Images Plus) With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) ...
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable ...
Madrigal Pharmaceuticals has delivered a very large 5 year gain for shareholders, and after that kind of rise the obvious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results